ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop their lead vaccine. The signing of the agreement is yet another milestone in a series of fruitful…
Björn von Siemens is co-founder and managing director of caresyntax GmbH. The company develops algorithms that analyze risk factors during surgery and provide decision support. The company, based in Berlin and Boston, recently raised 100 million US…
– Seventure Partners and Novartis Pharmaceuticals join as new investors
– Transformative treatment for millions of children with myopia
Berlin, Germany, July 14, 2021 — Dopavision, a company pioneering the development of digital therapeutics,…
Berlin, Germany and Duarte, USA, June 9, 2021:
ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening…
The purpose of this EU survey is to gain understanding on the needs of companies/organisations in the EU working on the development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication…
SPARK Europe will be regularly featured on the podcast series BioInnovation Spotlight “Shining a Light on The Next Big Thing“, a podcast series produced for and with LifeScience ORG.
Dr. Felix Lorenz, SPARKee and founder of the Berlin-based…
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced today that the U.S. National Institute of Allergy and Infectious Diseases…
Join one of our webinars to gain insights about this year’s partnership opportunities for digital health innovators with Bayer G4A!
We will reflect on the implications of the Covid-19 pandemic for digital health…
Berlin, May 12, 2021 - Today the 15th Speed Lecture Award took place as part of BIONNALE, again as a live-stream and with over 750 registrations.
A collaboration between Berlin, London, New York and Paris to leverage our collective innovation and speed our recovery from Covid-19
